Company Adaptive Biotechnologies Corporation

Equities

ADPT

US00650F1093

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:00 2024-03-28 pm EDT 5-day change 1st Jan Change
3.21 USD +11.07% Intraday chart for Adaptive Biotechnologies Corporation -3.60% -34.49%

Business Summary

Adaptive Biotechnologies Corporation is a commercial-stage biotechnology company. The Company is focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform applies its proprietary technologies to read the diverse genetic code of a patient’s immune system and understand precisely how the immune system detects and treats disease in that patient. It has business around two main areas: clinical assessment of minimal residual disease (MRD) in lymphoid malignancies and immune medicine (IM)-driven drug discovery and development. The MRD business focuses on the use of its highly sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. It comprises its clonoSEQ clinical diagnostic test, offered to clinicians, and its clonoSEQ assay, offered to biopharmaceutical partners, to advance drug development efforts (MRD Pharma).

Number of employees: 709

Sales per Business

USD in Million2022Weight2023Weight Delta
Minimal Residual Disease - Service
60.3 %
81 43.8 % 103 60.3 % +26.61%
Immune Medicine - Collaboration
25.0 %
66 35.8 % 43 25.0 % -35.86%
Immune Medicine - Service
14.7 %
32 17.1 % 25 14.7 % -21.46%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
100.0 %
185 100.0 % 170 100.0 % -8.11%

Managers

Managers TitleAgeSince
Founder 51 09-09-07
Chief Executive Officer 49 09-09-07
President 52 11-03-31
Director of Finance/CFO 51 22-03-08
Chief Tech/Sci/R&D Officer - -
Investor Relations Contact - -
Public Communications Contact - -
Comptroller/Controller/Auditor 40 21-10-27
General Counsel 64 19-02-28
Corporate Officer/Principal 50 14-08-31

Members of the board

Members of the board TitleAgeSince
Director/Board Member 61 13-01-31
Director/Board Member 68 13-12-31
Director/Board Member 58 18-02-12
Chief Executive Officer 49 09-09-07
Director/Board Member 58 19-02-28
Director/Board Member 55 21-03-16

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 145,092,271 142,101,405 ( 97.94 %) 0 97.94 %

Shareholders

NameEquities%Valuation
Viking Global Investors LP
20.67 %
29,993,708 20.67 % 123 M $
ARK Investment Management LLC
8.827 %
12,806,513 8.827 % 53 M $
Vanguard Fiduciary Trust Co.
8.800 %
12,767,684 8.800 % 52 M $
Matrix Capital Management Co. LP
7.977 %
11,572,590 7.977 % 48 M $
BlackRock Advisors LLC
7.516 %
10,904,130 7.516 % 45 M $
Nikko Asset Management Americas, Inc.
4.488 %
6,511,659 4.488 % 27 M $
Point72 Asset Management LP
2.566 %
3,722,500 2.566 % 15 M $
Pictet Asset Management Holding SA
2.359 %
3,422,356 2.359 % 14 M $
Aristotle Atlantic Partners LLC
2.103 %
3,050,684 2.103 % 13 M $
Rubric Capital Management LP
1.973 %
2,862,729 1.973 % 12 M $

Company contact information

Adaptive Biotechnologies Corp.

1165 Eastlake Avenue East

98109, Seattle

+206 659 0067

http://www.adaptivebiotech.com
address Adaptive Biotechnologies Corporation(ADPT)
  1. Stock
  2. Equities
  3. Stock Adaptive Biotechnologies Corporation - Nasdaq
  4. Company Adaptive Biotechnologies Corporation